Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs).
Dino Luethi, Daniel Trachsel, Marius C. Hoener, Matthias E. Liechti
Neuropharmacology May 15, 2018 DOI: 10.1016/j.neuropharm.2017.07.012 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vitro pharmacological study Peer reviewed |
|---|---|
| Population | Human cells transfected with monoamine receptors or transporters; rat and mouse TAAR1 |
| Intervention | 2C-T drugs |
| Keywords | New psychoactive substances Phenethylamines Psychedelics Powerful psychedelic effects These compounds Receptor engagement Interaction profiles High affinity Strongly activating them |
| Citations | 50 |
| Key points | 2C-T drugs have high affinity for 5-HT2A and 5-HT2C receptors and act as potent partial agonists at 5-HT2A and 5-HT2B receptors, predicting psychedelic effects mediated by 5-HT2 receptor interactions. |
Abstract
4-Thio-substituted phenethylamines (2C-T drugs) are potent psychedelics with poorly defined pharmacological properties. Because of their psychedelic effects, 2C-T drugs are sometimes sold as new psychoactive substances (NPSs). The aim of the present study was to characterize the monoamine receptor and transporter interaction profiles of a series of 2C-T drugs. We determined the binding affinities of 2C-T drugs at monoamine receptors and transporters in human cells that were transfected with the respective receptors or transporters. We also investigated the functional activation of serotonergic 5-hydroxytryptamine 2A (5-HT2A) and 5-HT2B receptors, activation of human trace amine-associated receptor 1 (TAAR1), and inhibition of monoamine uptake transporters. 2C-T drugs had high affinity for 5-HT2A and 5-HT2C receptors (1-54 nM and 40-350 nM, respectively). With activation potencies of 1-53 nM and 44-370 nM, the drugs were potent 5-HT2A receptor and 5-HT2B receptor, respectively, partial agonists. An exception to this were the benzylthiophenethylamines, which did not potently activate the 5-HT2B receptor (EC50 > 3000 nM). Furthermore, the compounds bound to serotonergic 5-HT1A and adrenergic receptors. The compounds had high affinity for the rat TAAR1 (5-68 nM) and interacted with the mouse but not human TAAR1. The 2C-T drugs did not potently interact with monoamine transporters (Ki > 4000 nM). The receptor binding profile of 2C-T drugs predicts psychedelic effects that are mediated by potent 5-HT2 receptor interactions. This article is part of the Special Issue entitled 'Designer Drugs and Legal Highs.'
Citations in the library
Cited by 29
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Acute Pharmacological Effects of 2C-B in Humans: An Observational Study Frontiers in Pharmacology March 13, 2018
- In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin Frontiers in Pharmacology April 29, 2024
- Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics Experimental Neurology June 4, 2021
- Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochemical Pharmacology June 1, 2019
and 24 more in the library
Cites 25
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
- Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European Neuropsychopharmacology May 20, 2016
- Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology December 1, 2015
- The new drug phenomenon Drug Testing and Analysis July 1, 2014
- Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study PLoS One May 4, 2012
and 20 more in the library